ANSM Issues Recall Notice for Boston Scientific Rapid Refill Continuous Injection System (9 July 2026)

Summary

On 9 July 2026, the French National Agency for the Safety of Medicines and Health Products (ANSM) published safety information concerning a recall by Boston Scientific of its Rapid Refill Continuous Injection System. The notice directs attention to medical device recall handling, lot traceability, post-market surveillance, field safety corrective actions in the EU market and communication channels with authorised representatives.

This article is compiled from publicly available information published by ANSM Medical Devices. Source: https://ansm.sante.fr/informations-de-securite/rapid-refill-continuous-injection-system-boston-scientific. The specific requirements of the competent authorities, as most recently and formally published, prevail.

Source and Scope

• Source authority: ANSM Medical Devices
• Date of original publication: 9 July 2026
• Article publication date: 9 July 2026, 17:48
• Source: ANSM Medical Devices
• Scope: Safety information and product recall notice concerning a specific device and lot range; not a general news item

The following text is a faithful English rendering of the substantive content of the ANSM page. Navigation elements, menus, site notices and other non-substantive material have been omitted. The link to the original text is retained above.

Full Translation of the Core Content

Safety Information: Boston Scientific Rapid Refill Continuous Injection System

Category: Medical device. Publication date: 9 July 2026.

ANSM has published information stating that it has been informed that Boston Scientific is conducting a lot recall concerning the Rapid Refill Continuous Injection System, under recall reference R2619855. The notified parties include the relevant hospital pharmacies in France.

According to the ANSM page, the users concerned have received the safety notice letter issued by the manufacturer. ANSM has recorded the safety action under the reference R2619855 as the regulatory registration number for this recall or field safety corrective action.

ANSM advises that users or institutions with questions about this safety action should contact the initiator of the action directly, namely Boston Scientific. The regulatory page also makes available the formal notice letter issued by the company on 9 July 2026 for reference by the users concerned.

The original text shows that this item constitutes medical device safety information and a product recall notice. Its purpose is not general news dissemination but to alert user institutions, hospital pharmacies and the responsible parties to the safety corrective arrangements for specific lots of the product. Companies should rely on the ANSM page and the formal notice letter from Boston Scientific to confirm the affected products, the lot range, the actions required of users and the subsequent communication pathway.

AIMEILI Regulatory Interpretation

What this notice means for medical device companies

When a recall or field safety corrective action notice of this kind is published by ANSM, companies should first determine whether it concerns a product of the same type, the same technical route, the same clinical use setting or the same risk profile as their own. This is not ordinary news: it is a public record by a regulator of a post-market safety event, of lot traceability and of the user notification mechanism.

For manufacturers that plan to enter the EU market or already sell there, notices of this kind relate directly to technical documentation, risk management, post-market surveillance (PMS), periodic safety update reports (PSUR), distributor communication and the responsibilities of the authorised representative. Even where a company's own product is not directly involved in this recall, the notice is a useful opportunity to verify that its recall procedures and field safety corrective actions can actually be executed in practice.

For Chinese manufacturers pursuing multi-country registration, securing the initial certificate is only the starting point. Recalls, safety notices, complaint trends and lot-related issues can all affect certificate renewal, changes, distributor relationships and regulatory trust. Companies are advised to log official notices such as this in their regulatory tracking register and to have regulatory affairs, quality, R&D and after-sales teams jointly determine whether documentation or internal procedures need to be updated.

Documentation to prioritise

Companies should prioritise a review of the following: intended use, classification rationale, ISO 13485 quality system evidence, risk management file, performance verification data, clinical evaluation or clinical evidence, labelling and instructions for use, authorisation documents and existing registration certificates.

Common Risks

• Unclear or unsupported classification decisions
• Incomplete evidence chains across the technical documentation
• Labelling and instructions for use not localised for the target market
• Unclear allocation of responsibilities with the authorised representative
• Insufficient arrangements for post-market maintenance and vigilance

AIMEILI View and Business Impact

Although this ANSM recall notice concerning the Boston Scientific Rapid Refill Continuous Injection System is addressed directly to hospital pharmacies in France, it carries significant implications for Chinese medical device manufacturers that plan to sell, or already sell, this type of product in the EU market. As a first step, companies should verify immediately whether their own products involve the same model or lot. Where a product carries CE marking and is in circulation in the EU, the company should assess in parallel whether reporting to the competent authority of the relevant member state, or a comparable recall action, is required.

From a registration perspective, a recall event of this kind may affect updates to the CE technical file, particularly the risk analysis and clinical evaluation sections. If the recall is caused by a design or manufacturing defect, the manufacturer must re-evaluate its risk management report and may need to supplement biocompatibility, performance verification or stability test data. At the same time, warnings or changes to the conditions of use may need to be added to the labelling and instructions for use.

From a quality system perspective, the recall underscores the need to strengthen post-market surveillance (PMS) procedures. Chinese manufacturers should establish effective complaint handling and lot traceability mechanisms so that affected products can be identified quickly and corrective actions implemented. In addition, companies that access the market through an EU authorised representative (AR) must work closely with that AR to ensure that PSURs and trend reports are submitted to the competent authorities in a timely manner.

Finally, companies in this product area are advised to monitor any investigation conclusions or corrective action requirements that ANSM may publish subsequently. They should also check whether the product is covered by domestic registration or export registration and prepare a communication strategy in advance, so that compliance risks arising from delayed information do not materialise. AIMEILI can assist companies in assessing the impact of a recall, updating technical documentation and managing the communication process with regulatory authorities.

Turning the notice into actionable compliance steps

In international medical device registration practice, information of this kind published by ANSM Medical Devices should not be read as ordinary news. A company must first determine whether the item concerns regulatory policy, guidance or standards, product approval, recall and safety, quality systems or post-market oversight, because each category triggers different internal actions. Where a company is running a registration project for the relevant market, the update should be entered in the target-market regulatory tracking table and reviewed to establish whether it affects product classification, the registration pathway, the applicant entity, local agent responsibilities or certificate maintenance arrangements.

For Chinese medical device manufacturers, the practical impact of the ANSM notice of 9 July 2026 concerning the Boston Scientific Rapid Refill Continuous Injection System is typically felt in documentation consistency and evidence-chain management. Companies should review their existing technical file, risk management report, performance verification data, clinical evaluation or clinical evidence, labelling and instructions for use, quality system certificates and post-market surveillance documentation to confirm that these still support the latest regulatory expectations in the target market. Where the notice concerns a safety notification, a recall, a product approval or a regulatory meeting, companies should also assess whether products of the same type, the same technical route or the same risk profile are likely to attract particular scrutiny from reviewers.

At the operational level, AIMEILI recommends three actions. First, record the official source link, publication date, product scope and potentially affected areas in the regulatory tracking register. Second, have regulatory affairs, quality, R&D and sales jointly determine whether labelling, instructions for use, clinical evaluation, risk management or test reports need to be updated. Third, where the product is already marketed locally or an application has already been submitted, assess in parallel whether the local agent, importer, distributor and after-sales team need to take communication, change notification, supplementary clarification or post-market monitoring measures.

The value of a notice of this kind lies not in simply knowing what a regulator has published, but in converting public information into executable compliance actions. For companies preparing multi-country registrations, particular attention should be paid to the boundaries of documentation reuse between markets: the same set of CE, FDA, NMPA, ISO 13485 or MDSAP documentation may serve as core evidence in one country while requiring localised explanations, translated labelling, authorised representative documents or a post-market maintenance plan in another. AIMEILI recommends that companies carry out a brief documentation gap review after every significant regulatory update, so that they are not placed on the back foot during later deficiency responses, change notifications or certificate renewals.

FAQ

Can the ANSM notice of 9 July 2026 on the Boston Scientific Rapid Refill Continuous Injection System be used directly as a basis for a regulatory submission?

No. This article is intended to support preliminary understanding and project assessment only. A formal submission must be based on the most current requirements of the regulatory authority in the target country, the concluded product classification and the company's actual documentation.

What should a company do first after seeing an update of this kind?

A company should begin with a documentation gap assessment to determine whether the update affects its registration pathway, technical file, labelling, quality system or post-market maintenance obligations.

Content Review and Scope of Application

• Author: AIMEILI Regulatory Editorial Team
• Professional review: AIMEILI International Medical Device Registration Project Team
• Source principles: Official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials are given priority; industry media and project experience are used only as supporting judgement.
• Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the regulatory authority in the target country, testing conclusions or legal advice.

Need to assess a registration pathway?

Please provide the product name, intended use, target countries and the documentation currently available. AIMEILI can assist in determining the registration pathway, identifying documentation gaps and assessing compliance risk.